Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials.
Karama AslehDongsheng TuDongxia GaoVivien BramwellMark N LevineKathleen I PritchardLois E ShepherdTorsten O NielsenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The nestin/INPP4B IHC panel identifies women with basal breast cancers who benefit from nonanthracycline chemotherapy but not endocrine adjuvant treatments.